LY2886721 - CAS 1262036-50-9
Catalog number: 1262036-50-9
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
Molecular Weight:
LY2886721, under the IUPAC name N-(3-(2-amino-4a,5,7,7a-tetrahydro-4H-furo(3,4-d)(1,3)thiazin-7a-yl)-4-fluorophenyl)-5-fluoropicolinamide, is the first oral small molecule inhibitting Beta secretase (BACE) to reach Phase 2 clinical research. It was developed by Eli Lilly & Co. with the potention to treat Alzheimer's Disease.
Publictions citing BOC Sciences Products
  • >> More
Brife Description:
The first oral small molecule inhibit Beta secretase (BACE) to reach Phase 2 clinical research.
Related CAS:
262036-49-6 (HCl )
Solid powder
N-(3-((4aS,7aS)-2-amino-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]thiazin-7a-yl)-4-fluorophenyl)-5-fluoropicolinamide; LY2886721; LY-2886721; LY 2886721
Soluble to 28mg/mL in DMSO
Store in a cool and dry place and at 0 - 4℃ for short term (days to weeks) or -44℃ for long term (months to years).
Canonical SMILES:
1.The potent BACE1 inhibitor LY2886721 elicits robust central Aβ pharmacodynamic responses in mice, dogs, and humans.
May PC1, Willis BA1, Lowe SL2, Dean RA1, Monk SA1, Cocke PJ1, Audia JE1, Boggs LN1, Borders AR1, Brier RA1, Calligaro DO1, Day TA1, Ereshefsky L3, Erickson JA1, Gevorkyan H4, Gonzales CR1, James DE1, Jhee SS3, Komjathy SF1, Li L1, Lindstrom TD1, Mathes BM J Neurosci. 2015 Jan 21;35(3):1199-210. doi: 10.1523/JNEUROSCI.4129-14.2015.
BACE1 is a key protease controlling the formation of amyloid β, a peptide hypothesized to play a significant role in the pathogenesis of Alzheimer's disease (AD). Therefore, the development of potent and selective inhibitors of BACE1 has been a focus of many drug discovery efforts in academia and industry. Herein, we report the nonclinical and early clinical development of LY2886721, a BACE1 active site inhibitor that reached phase 2 clinical trials in AD. LY2886721 has high selectivity against key off-target proteases, which efficiently translates in vitro activity into robust in vivo amyloid β lowering in nonclinical animal models. Similar potent and persistent amyloid β lowering was observed in plasma and lumbar CSF when single and multiple doses of LY2886721 were administered to healthy human subjects. Collectively, these data add support for BACE1 inhibition as an effective means of amyloid lowering and as an attractive target for potential disease modification therapy in AD.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related β-secretase Products

(CAS: 1227163-56-5)

AZD3839, with the potential to treat Alzheimer’s disease, was reported as a selective BACE1 inhibitor (IC50=4.8μM) for which concentration-dependent lowering of...

CAS 797035-11-1 BACE-1 Inhibitor

BACE-1 Inhibitor
(CAS: 797035-11-1)

BACE-1 Inhibitor is a potent, selective and cell-permeable inhibitor of human β-secretase (BACE-1) binding to the active site of BACE-1. It inhibits secretion o...

(CAS: 1628076-74-3)

AZD3293, a spiro compound, has been found to be a β-secretase inhibitor that has good blood-brain barrier penetration and could probably be significant in studi...


VTP-37948, also called BI 1181181, being clinically developed with Boehringer Ingelheim and Vitae Pharmaceuticals, is a is an inhibitor targeted to the catalyti...


PF-05297909, is a BACE inhibitor developed by Pfizer. Phase 1

CAS 1254166-60-3 Imidazo[1,2-a]pyridine-2-carboxamide, 6-chloro-N-[6-(phenylmethoxy)-1H-benzimidazol-2-yl]-

Imidazo[1,2-a]pyridine-2-carboxamide, 6-
(CAS: 1254166-60-3)

An inhibitor of β-site amyloid precursor protein-cleaving enzyme (BACE)

CAS 989-51-5 EGCG

(CAS: 989-51-5)

EGCG, also called Epigallocatechin gallate, under the IUPAC name [(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl] 3,4,5-trihydroxy...


E2609, developed by Eisai Inc, is a novel, small molecule, BACE1 inhibitor that has been shown in nonclinical studies to inhibit the production of Aβ40 and Aβ42...

CAS 244081-42-3 Rafabegron

(CAS: 244081-42-3)

Rafabegron is a potent and selective beta3-adrenoceptor agonist.

CAS 1194044-20-6 LY2811376

(CAS: 1194044-20-6)

LY2811376, under the IUPAC name (4S)-4-(2,4-difluoro-5-pyrimidin-5-ylphenyl)-4-methyl-5,6-dihydro-1,3-thiazin-2-amine, is the first orally available non-peptidi...


CTS-21166, the selective BACE1 inhibitor whose structure is not revealed, reduce brain Aβ levels by over 35% and plaque load by 40%. Phase 1 IC50=1.2–3.6 nM (ce...

CAS 1262036-49-6 LY 2886721 hydrochloride

LY 2886721 hydrochloride
(CAS: 1262036-49-6)

LY 2886721 hydrochloride is the first oral inhibitor of human β-secretase (BACE-1) with the potential to treat Alzheimer's Disease.

(CAS: 365276-12-6)

TAK-070, under the IUPAC name 2-​Naphthaleneethanamin​e, 6-​([1,​1'-​biphenyl]​-​4-​ylmethoxy)​-​1,​2,​3,​4-​tetrahydro-​N,​N-​dimethyl-​, hydrochloride, hydrat...

(CAS: 1286770-55-5)

Verubecestat, a iminothiadiazine dioxide compound, is an oral BACE1 inhibitor originated by Merck & Co. It can bind significantly to β-secretase. Verubecestat h...

(CAS: 1215868-94-2)

This active molecular is a potent BACE1 inhibitor that is a potential target for the treatment of Alzheimer's disease. AMG-8718 produced significantly reduction...

(CAS: 1628077-06-4)

RG7129, developed by Roche, inhibit BACE to treat Alzheimer's disease. Phase-I

CAS 1262036-50-9 LY2886721

(CAS: 1262036-50-9)

LY2886721, under the IUPAC name N-(3-(2-amino-4a,5,7,7a-tetrahydro-4H-furo(3,4-d)(1,3)thiazin-7a-yl)-4-fluorophenyl)-5-fluoropicolinamide, is the first oral sma...

(CAS: 1227163-84-9)

AZD3839, also called CHEMBL2177913, as a a potent BACE1 inhibitor it is a clinical candidate for the treatment of Alzheimer's disease. Studies indicate that the...


HPP854, developed by High Point Pharmaceuticals, is a small molecule BACE1 protein inhibitor. Phase 1

CAS 1383982-64-6 Lanabecestat

(CAS: 1383982-64-6)

Lanabecestat, also referred to AZD3293,is an orally active and highly permeable potent inhibitor of human β-secretase 1 in clinical development for the treatmen...

Chemical Structure

CAS 1262036-50-9 LY2886721

Quick Inquiry

Verification code

Featured Items